741 related articles for article (PubMed ID: 17059563)
1. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
2. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration.
Engel T; Lucas JJ; Gómez-Ramos P; Moran MA; Avila J; Hernández F
Neurobiol Aging; 2006 Sep; 27(9):1258-68. PubMed ID: 16054268
[TBL] [Abstract][Full Text] [Related]
3. Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta.
Engel T; Goñi-Oliver P; Gomez-Ramos P; Morán MA; Lucas JJ; Avila J; Hernández F
Neuroscience; 2008 Dec; 157(4):772-80. PubMed ID: 18951953
[TBL] [Abstract][Full Text] [Related]
4. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.
Chen S; An FM; Yin L; Liu AR; Yin DK; Yao WB; Gao XD
Neuroscience; 2014 Jan; 256():137-46. PubMed ID: 24183963
[TBL] [Abstract][Full Text] [Related]
6. GSK3 and tau: two convergence points in Alzheimer's disease.
Hernandez F; Lucas JJ; Avila J
J Alzheimers Dis; 2013; 33 Suppl 1():S141-4. PubMed ID: 22710914
[TBL] [Abstract][Full Text] [Related]
7. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ
J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661
[TBL] [Abstract][Full Text] [Related]
9. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
Chauhan NB; Siegel GJ; Feinstein DL
Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
[TBL] [Abstract][Full Text] [Related]
10. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
11. Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.
Jin N; Yin X; Yu D; Cao M; Gong CX; Iqbal K; Ding F; Gu X; Liu F
Sci Rep; 2015 Feb; 5():8187. PubMed ID: 25641096
[TBL] [Abstract][Full Text] [Related]
12. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
13. 17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.
Shi HR; Zhu LQ; Wang SH; Liu XA; Tian Q; Zhang Q; Wang Q; Wang JZ
J Neural Transm (Vienna); 2008 Jun; 115(6):879-88. PubMed ID: 18217188
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide induces tau hyperphosphorylation via glycogen synthase kinase-3beta activation.
Zhang YJ; Xu YF; Liu YH; Yin J; Wang JZ
FEBS Lett; 2005 Nov; 579(27):6230-6. PubMed ID: 16253246
[TBL] [Abstract][Full Text] [Related]
15. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Caccamo A; Oddo S; Tran LX; LaFerla FM
Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
[TBL] [Abstract][Full Text] [Related]
16. A mouse model to study tau pathology related with tau phosphorylation and assembly.
Engel T; Lucas JJ; Hernández F; Avila J
J Neurol Sci; 2007 Jun; 257(1-2):250-4. PubMed ID: 17362999
[TBL] [Abstract][Full Text] [Related]
17. Expression of an altered form of tau in Sf9 insect cells results in the assembly of polymers resembling Alzheimer's paired helical filaments.
Gómez-Ramos A; Abad X; López Fanarraga M; Bhat R; Zabala JC; Avila J
Brain Res; 2004 May; 1007(1-2):57-64. PubMed ID: 15064135
[TBL] [Abstract][Full Text] [Related]
18. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Noble W; Planel E; Zehr C; Olm V; Meyerson J; Suleman F; Gaynor K; Wang L; LaFrancois J; Feinstein B; Burns M; Krishnamurthy P; Wen Y; Bhat R; Lewis J; Dickson D; Duff K
Proc Natl Acad Sci U S A; 2005 May; 102(19):6990-5. PubMed ID: 15867159
[TBL] [Abstract][Full Text] [Related]
20. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
